The impact of direct-acting antiviral treatment on lipid metabolism and insulin resistance in chronic hepatitis C patients: temporary? permanent?

Background/Aims: In previous studies that investigated the impact of direct-acting antiviral (DAA) treatment on lipid metabolism and insulin resistance (IR) in chronic hepatitis C patients, the end-of-treatment or posttreatment values have been compared with baseline values. The results are inconsis...

Full description

Saved in:
Bibliographic Details
Published in:The Turkish journal of gastroenterology 2020-05, Vol.31 (5), p.384-392
Main Authors: Ozdogan, Osman, Yaras, Serkan, Ates, Fehmi, Ucbilek, Enver, Sezgin, Orhan, Altintas, Engin
Format: Article
Language:English
Subjects:
Care and treatment
Cholesterol
Comparative analysis
Diabetes therapy
Hepatitis C
Hepatitis C virus
Insulin resistance
Low density lipoproteins
Medical research
Medicine, Experimental
Original
Physiological aspects
Protease inhibitors
Triglycerides
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background/Aims: In previous studies that investigated the impact of direct-acting antiviral (DAA) treatment on lipid metabolism and insulin resistance (IR) in chronic hepatitis C patients, the end-of-treatment or posttreatment values have been compared with baseline values. The results are inconsistent. We evaluated patients during and after the treatment. Materials and Methods: A total of 121 patients were included in the study. Of these, 93 patients were treated with sofosbuvir/ledipasvir[+ or -]ribavirin (RBV), and 28 patients were treated with ombitasvir/paritaprevir/ritonavir+dasabuvir[+ or -]RBV. Total cholesterol (TC), low-density lipoprotein (LDL), triglyceride (TG), and homeostatic model assessment-insulin resistance (HOMA-IR) levels were measured at the onset of treatment, after the first month of treatment, at the end of treatment, and at 6 and 12 months after the end of treatment. Results: A total of 117 patients were genotype 1. Sustained virological response was 98.4%. HOMA-IR values during treatment were significantly higher than at the beginning of treatment (p=0.0001). At 12 months, there was a decrease in HOMA-IR, but this was not statistically significant (p=0.2048). TC and LDL levels were significantly increased in the first month of treatment (TC: 159[+ or -]30, 180[+ or -]34 mg dL-1 and LDL: 84[+ or -]28, 100[+ or -]30 mg dL-1) (p
ISSN:1300-4948
2148-5607
DOI:10.5152/tjg.2020.19273